
Gilead Sciences to acquire CAR-T company Arcellx
Gilead Sciences has entered into a definitive agreement to acquire Arcellx for an equity value of $7.8 billion. Arcellx is a biotechnology company focused on delivering a new class of immunotherapies for patients with cancer and other incurable diseases. The companies have an existing collaboration… Read More



